Spencer Knight: Hereโs the current 34 approval breakdown by therapeutic area
Spencer Knight, Senior Business Consultant of Cell and Gene Therapy at Charlton Morris, shared on LinkedIn:
“5 approvals in the last 6 months!
Updated graphic below reflects the two new FDA approvals achieved on Friday by Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio in sickle cell disease. From 32 to now 34 approvals since our last post.
Hereโs the current 34 approval breakdown by therapeutic area:
๐๐๐๐ฆ๐๐ญ๐จ๐ฅ๐จ๐ ๐ฒ (20 products):
– 2 for the treatment of multiple myeloma
– 4 for the treatment of lymphoma
– 2 for haemophilia
– 10 for cell transplant-based therapies
– 2 recently approvals for sickle cell disease: ๐๐๐๐๐๐๐ and ๐๐๐
๐๐๐๐๐.
๐๐ง๐๐จ๐๐ซ๐ข๐ง๐จ๐ฅ๐จ๐ ๐ฒ (1 product).
๐๐ฉ๐ก๐ญ๐ก๐๐ฅ๐ฆ๐จ๐ฅ๐จ๐ ๐ฒ (1 product).
๐๐ง๐๐จ๐ฅ๐จ๐ ๐ฒ (3 products).
๐๐๐ฎ๐ซ๐จ๐ฅ๐จ๐ ๐ฒ (3 products).
๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐๐๐๐ข๐๐ข๐๐ง๐๐ฒ (1 product).
๐๐ฎ๐ฌ๐๐ฎ๐ฅ๐จ๐ฌ๐ค๐๐ฅ๐๐ญ๐๐ฅ (1 product).
๐๐๐ซ๐ฆ๐๐ญ๐จ๐ฅ๐จ๐ ๐ฒ (3 products).
๐๐๐ฌ๐ญ๐ก๐๐ญ๐ข๐ ๐๐ฉ๐ฉ๐ฅ๐ข๐๐๐ญ๐ข๐จ๐ง๐ฌ (1 product).
This diverse range of approved products underscores the expanding impact of CGT across various medical fields.
34 approvals is certainly positive, however, our industry MUST address manufacturing challenges early in the development process to ๐๐ง๐ฌ๐ฎ๐ซ๐ ๐ญ๐ก๐ ๐๐จ๐ฆ๐ฆ๐๐ซ๐๐ข๐๐ฅ ๐ฏ๐ข๐๐๐ข๐ฅ๐ข๐ญ๐ฒ of these therapies. Thanks to Jason Foster and Sanjay Srivastava for recently speaking on this.
๐๐ฉ๐ข๐ต ๐ฏ๐ฆ๐ฆ๐ฅ๐ด ๐ต๐ฐ ๐ฃ๐ฆ ๐ข๐ฅ๐ฅ๐ฆ๐ฅ? Thanks again for allowing me to share this and hope you liked the red arrow contribution lol – Joanna Sadowska.
P.S. – Want to stay ahead of the biotech revolution? Sign up for FREE to this week’s ๐๐๐๐ฐ๐๐๐ค๐ฅ๐ฒ newsletter and discover the latest breakthroughs and advancements, here.”
Source: Spencer Knight/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023